srch

14.03.2022 · The drop-down demerger is expected to be completed during June 2022, subject to the approval by the Annual General Meeting. For further information, please contact: Erik Digman Wiklund, CEO. Phone: +47 413 33 536. Email: erik.wiklund@targovax.com. Renate Birkeli, Investor Relations. Phone: +47 922 61 624. Email: renate.birkeli@targovax.com.

07.03.2022 · Investors & Media. Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene ...

Investors & Media. Renate Birkeli. Investor Relations. renate.birkeli@targovax.com. Telephone: +47 922 61 624. Share. PRINT; STAY CONNECTED.

Mar 07, 2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax's focus is to activate the patient's immune system to...

Webcast presentation on Xtrainvestor ... For a company presentation in Norwegian, please see video below. ... Targovax is a clinical stage immuno-oncology company ...

Mar 07, 2022 · Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials. IR Contact Renate Birkeli Investor Relations renate.birkeli@targovax.com

Company presentation January · Capital markets day 2021. CAPITAL MARKETS DAY With strong clinical data generated on ONCOS-102, Targovax is moving into ...

Report, Presentation, Webcast, ESEF, ESEF (view XBRL). March 9, 2022 Annual Report 2021. February 17, 2022 Q4 Fourth Quarter 2021.

28.02.2022 · In Targovax, Dr. Gaal's core responsibilities will be to oversee all financial, investor relations and business development activities, as well as playing an integral role in defining and ...

Investor, Number of Shares, % of top 20, % of total, Type, Country. Avanza Bank AB, 16 693 889, 19,73%, 8,86%, NOM, SWE.

On 9 March 2022, the Board of Directors of Targovax ASA approved the Company's Annual Report, including the financial statements for 2021, ...

May 21, 2021 · Targovax ASA is about to announce its earnings — here's what Wall Street expects Markets Insider Automation 187d Targovax to present at upcoming investor and scientific conferences

Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology ...

Mar 14, 2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives.

Nov 04, 2021 · Targovax's CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below). ... Investor Relations Phone: +47 922 61 ...

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune ... Investor Relations. renate.birkeli@targovax.com ...

07.03.2022 · Email: erik.wiklund@targovax.com. Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com. Media enquiries: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no . About Targovax. Activating the patient's immune system to fight cancer

May 21, 2021 · May. 21, 2021, 01:19 AM. OSLO, Norway, May 21, 2021 /PRNewswire/ -- Targovax ASA, today announces that members of its executive management team is invited to present at upcoming conferences. ABGSC ...

IR contact. Renate Birkeli. Investor Relations ... An online presentation by Targovax's management to investors, analysts and the press will take place at ...

07.03.2022 · Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquiries: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas ...

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

07.03.2022 · The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s ...

Prospectus for the listing on Oslo Axess can be downloaded here (Subscription period expired 8. August 2016 at 16:00 hours CET). IR contact ...

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax's